FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Cytokine topics
Antibodies
Inflammation
Specificity
Immunotherapy
Major Histocompatibility Complex
Compatibility
Combination Therapy
Histocompatibility
Immune Response
Monoclonal Antibody
Stimulator
Therapeutics
Immunostimulator
Monoclonal
Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cytokine patents



      
           
This page is updated frequently with new Cytokine-related patent applications. Subscribe to the Cytokine RSS feed to automatically get the update: related Cytokine RSS feeds. RSS updates for this page: Cytokine RSS RSS


Engineered antibody-interferon mutant fusion molecules

Snu R&db Foundation

Cytokine adsorption sheet, method for manufacturing the same, and blood filter comprising the same

Date/App# patent app List of recent Cytokine-related patents
05/21/15
20150141332
 Methods for diagnosing osteoarthritis patent thumbnailMethods for diagnosing osteoarthritis
Methods for managing osteoarthritis, in a human or other mammalian subject, comprising the measurement of certain cytokines and growth factors in a tissue sample of a subject, including one or more of platelet-derived growth factor ab (pdgf-ab), platelet-derived growth factor bb (pdgf-bb), and epidermal growth factor (egf). Tissue samples may be whole blood, blood fractions, urine, saliva, and synovial fluid.
Biomet Biologics, Llc
05/21/15
20150140112
 Composition comprising extract of mixture of undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis patent thumbnailComposition comprising extract of mixture of undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis
The present invention relates to a composition comprising an extract of a mixture of undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis, wherein the composition has the excellent effect of treating atopic dermatitis through the synergistic interaction of the anti-inflammatory effect of undaria pinnatifida sporophylls and the cell regenerative effect of ascidian shells. The composition of the invention is not involved in the suppression of cytokine production.
Industry-academic Cooperation Foundation Gyeongsang National University
05/21/15
20150139951
 Engineered antibody-interferon mutant fusion molecules patent thumbnailEngineered antibody-interferon mutant fusion molecules
The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (taa) antibody (ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell.
Immungene Inc.
05/21/15
20150136693
 Cytokine adsorption sheet,  manufacturing the same, and blood filter comprising the same patent thumbnailCytokine adsorption sheet, manufacturing the same, and blood filter comprising the same
A cytokine adsorption sheet comprises a nanofiber web formed by electrospinning a spinning solution prepared by mixing an adsorbent material capable of adsorbing cytokine and an electrospinnable polymer material. Thus, the dissolution of the adsorbent material by blood can be prevented..
Snu R&db Foundation
05/14/15
20150132443
 Purification program patent thumbnailPurification program
A method for a mammal to remove toxins from the mammal's system, the method includes the steps of providing instructions for the mammal to ingest a set of substances periodically according to a set of instructions and to practice a set of wellness regimen periodically. The set of instructions comprises instructing the mammal to periodically ingest a predetermined amount of a rejuvenating substances providing the mammal with support of antioxidant activity, cytokine balance, detoxification, gastrointestinal and liver health; a predetermined amount of soluble dietary fiber substances; a predetermined amount of grasses; a predetermined amount of an antioxidant substances providing the mammal with support of antioxidant activities; predetermined amount of omega fatty acid substances and a predetermined amount of green tea.
05/14/15
20150132343
 System and  the detection and treatment of infection by a microbial agent associated with hiv infection patent thumbnailSystem and the detection and treatment of infection by a microbial agent associated with hiv infection
A method of treating a patient, comprising administering at least one antibiotic, e.g., doxycycline and ciprofloxacin, sufficient to substantially treat an intracellular bacterial organism present in at least erythrocytes, e.g., over a course of at least two weeks; and subsequently administering at least one immunostimulant, e.g., which directly or indirectly increases levels of immunostimulatory cytokines in the patient, and at least one antioxidant, e.g., glutathione, to effectively treat a coinfection of the patient with a virus. The intracellular bacterial organism may be a rickettsiales-like organism, and the virus may be hiv..
05/14/15
20150132287
 Methods of decreasing leptin levels or activity for treating inflammation patent thumbnailMethods of decreasing leptin levels or activity for treating inflammation
The present invention is directed to methods for modulating the th/th2 cell balance toward anti-inflammatory cytokine producing cells in a subject comprising decreasing the amount, the expression, or the activity of leptin in a subject sufficient to modulate the th1/th2 cell balance toward anti-inflammatory cytokine producing cells. The invention is also directed to methods of treatment of an immune-related disorder in a subject comprising decreasing the amount, the expression, or the activity of leptin in the subject sufficient to treat the immune-related disorder..
05/07/15
20150127105
 Method of treating scoliosis using a biological implant patent thumbnailMethod of treating scoliosis using a biological implant
The present invention is a bone growth stimulating and promoting cytokine type biological implant preferably comprising pth coated with a controlled release biodegradable coating that is implanted preferably in the concave side of a scoliotically curved spine in combination with a bone growth inhibiting type biological implant preferably comprising methotrexate or like anti-metabolite coated with a controlled release biodegradable coating that is implanted preferably in the convex side of a scoliotically curved spine. The insertion of the biological implant is highly non-invasion, especially as compared to more conventional spine surgical methods, and the biological implant does not decrease spinal mobility or spinal range of motion..
05/07/15
20150126709
 Trail collectin fusion proteins patent thumbnailTrail collectin fusion proteins
The present invention refers to a fusion protein comprising a tnf-superfamily (tnfsf) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof.
Apogenix Gmbh
05/07/15
20150126480
 Biomarker of renal dysfunction patent thumbnailBiomarker of renal dysfunction
The present invention relates to a method for a method for predicting the development of renal dysfunction in a subject following physical trauma, hypotension, sepsis and/or septic shock syndrome, wherein the method comprises the steps of: —a. Determining the level of an anti-inflammatory cytokine present in a sample taken from the subject after physical trauma, after a hypotensive event, after sepsis, and/or after septic shock syndrome; b.
Belfast Health And Social Care Trust
05/07/15
20150125421

Cytokine-based fusion proteins for treatment of immune disorders


The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the fusion proteins are also provided..
East Carolina University
05/07/15
20150125419

Trail single chain molecules


The present invention refers to single-chain fusion proteins comprising three soluble tnf superfamily (tnfsf) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications..
Apogenix Gmbh
04/30/15
20150119409

Compositions and methods for the treatment of inflammatory disorders


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for treating or preventing inflammatory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
04/23/15
20150111823

Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue


The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hghrelin.. .
Ipsen Pharma S.a.s.
04/23/15
20150110790

Composition for modulating the expression of cell adhesion molecules


A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a method of modulating or attenuating the cytokine induced cell surface expression of a cell adhesion molecule in a patient by administering to a digoxin antibody composition to a patient in need of such treatment..
Cda Royalty Investors, Llc
04/23/15
20150110753

Biomatrix scaffolds


The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same.. .
The University Of North Carolina At Chapel Hill
04/23/15
20150110734

Trail single chain molecules


The present invention refers to single-chain fusion proteins comprising three soluble tnf superfamily (tnfsf) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications..
Apogenix Gmbh
04/16/15
20150105400

Therapeutic agent for cerebral infarction


The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as tnf-β, il-1β, il-6 and mcp-1 and the like..
Mitsubishi Tanabe Pharma Corporation
04/16/15
20150104483

Therapeutic agent for cerebral infarction


The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as tnf-α, il-1β, il-6 and mcp-1 and the like..
Mitsubishi Tanabe Pharma Corporation
04/16/15
20150104414

Cytokines and neuroantigens for treatment of immune disorders


The present invention provides methods of regulating an immunological disorder comprising administering to a subject an effective amount of (i) an autoimmune antigen in conjunction with (ii) an anti-inflammatory cytokine. Compositions including the same are also provided..
East Carolina University
04/16/15
20150104410

Serpin fusion polypeptides and methods of use thereof


This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an fc polypeptide or an amino acid sequence that is derived from an fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a wap domain containing polypeptide or a sequence derived from a wap containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules..
Inhibrx Biopharma Llc
04/16/15
20150103591

Semiconductor memory with integrated biologic element


A memory includes cytokines, such as macromolecule proteins, as a poly-state data storage. Each fold state of multiple fold states of a protein are associated with a data value.
Toshiba America Electronic Components, Inc.
04/09/15
20150100100

Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation


A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist.
04/09/15
20150099652

In vitro process for the quick determination of a patient's status relating to infection with mycobacterium tuberculosis


An in-vitro process for the quick determination of the infection status of a mycobacterium tuberculosis infection from whole blood in terms of active or latent tuberculosis, comprising the steps of: stimulating an antigen-specific t cell that is present in a first sample of whole blood with purified protein derivative (ppd) in the presence of antibodies against cd28, or cd28 and cd49d; processing of ppd by antigen-presenting coils (apc) by incubating for 1.5 h to 2.5 h, especially for 2 h, at 35° c. To 39° c., especially at 37° c., optionally with raiding c02; then adding a secretion inhibitor; effecting an intensive mixing; and another incubation for a period of at least 2.5 h at a temperature of from 35° c.
Red Flag Diagnostics Gmbh
04/02/15
20150094285

Phytochemical compositions including sesamin for anti-inflammatory, anti-cytokine storm, and other uses


A composition (e.g., phytochemical composition) including sesamin, the composition exhibiting anti-inflammatory, anti-cytokine storm, connective tissue preservation, anti-viral, and/or other properties in biological tissue. The phytochemical composition therapeutically affects a pro-inflammatory cytokine condition, for instance facilitating or effectuating decrease in a quantity of a pro-inflammatory cytokine, for example, interleukin-1 and tumor necrosis-alpha.
Chiang Mai University
04/02/15
20150093463

Nutritional composition containing a peptide component with anti-inflammatory properties and uses thereof


The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising seq id no 4, seq id no 13, seq id no 17, seq id no 21, seq id no 24, seq id no 30, seq id no 31, seq id no 32, seq id no 51, seq id no 57, seq id no 60, and seq id no 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e.
Mead Johnson Nutrition Company
03/26/15
20150087818

Chimeric il-1 receptor type i agonists and antagonists


Featured herein are non-naturally occuring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive to interleukin-1 receptor i (il-1ri), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, β strands, and loops from at least two parental cytokines domains..
Eleven Biotherapeutics, Inc.
03/26/15
20150087660

Compositions and methods for the treatment of chronic diseases and inflammatory disorders


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of chronic diseases and inflammatory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
03/26/15
20150086583

Mucin-associated surface protein as vaccine against chagas disease


Use of synthetic peptides derived from trypanosoma cruzi antigens and their use in vaccination against trypomastigote infection and chagas disease. T.
Board Of Regents, The University Of Texas System
03/26/15
20150086550

Combination of the application of antibodies for immunostimulation together with glucocorticoids


The present invention relates to methods for reducing or eliminating the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. Additionally, the present invention relates to a pharmaceutical composition that contains at least one immunostimulating antibody and at least one glucocorticoid..
03/26/15
20150086508

Compositions and methods for enhancing epidermal repair and cutaneous innate immunity


The invention disclosed herein relates to the field of epidermal repair and skin innate immunity. More particularly, the invention concerns the use of a mix of cytokines to inhibit keratinocyte differentiation, activate skin innate immunity, increase the expression of anti-microbial peptides, and improve epidermal repair.
03/26/15
20150086480

Heteroaryl inhibitors of pde4


The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (pde4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.. .
Tetra Discovery Partners, Llc
03/19/15
20150080885

Methods for bilateral renal neuromodulation


Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
03/19/15
20150080884

Methods for monopolar renal neuromodulation


Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
03/19/15
20150080873

Methods for therapeutic renal neuromodulation


Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
03/19/15
20150080481

Methods for renal neuromodulation


Methods and apparatus are provided for treating contrast nephropathy, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
03/19/15
20150080419

5-substituted quinazolinone derivatives and compositions comprising and methods of using the same


Provided are 5-substituted quinazolinone compounds, for example, of formula (i), and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use for treating angiogenesis or cytokine related disorders, and pharmaceutical compositions of these compounds are disclosed..
Celgene Corporation
03/19/15
20150079190

Immortalized cell compositions and compositions derived therefrom


The invention is directed to immortalized cell compositions and compositions derived therefrom. The invention is further directed to methods of making and using such immortalized cell compositions and compositions derived therefrom.
Stemnion, Inc.
03/19/15
20150079116

Diagnostic tools for response to 6-thiopurine therapy


Nk cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein..
The Regents Of The University Of California
03/19/15
20150079048

Method for in vivo, ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling


A method for in vivo, ex vivo and in vitro regeneration of cartilage and collagen. In vivo, ex vivo and in vitro regeneration and de novo formation of articular cartilage and collagen by intermittently applied hydrostatic pressure.
The Board Of Trustees Of The Leland Stanford Junior University
03/19/15
20150079026

Controlled release formulations for the induction and proliferation of blood cells


The absence of regulatory t cells (treg) may underlie disorders including but not limited to autoimmunity, dermatitis, periodontitis and even transplant rejection. Enhancing local numbers of treg through in situ treg expansion or induction is contemplated herein as a treatment option for these disorders.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
03/12/15
20150072889

Systems and methods for detecting infectious diseases


Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (pos) location and may be tested at the pos location for multiple markers for multiple diseases, including upper and lower respiratory diseases.
Theranos, Inc.
03/12/15
20150072338

Systems and methods for detecting infectious diseases


Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (pos) location and may be tested at the pos location for multiple markers for multiple diseases, including upper and lower respiratory diseases.
Theranos, Inc.
03/12/15
20150071967

Tolerisation-inducing composition


The present invention relates to a composition comprising a tolerogenic peptide and a gsk-3 inhibitor and uses thereof. The invention also relates to the use of a gsk-3 inhibitor to accelerate the peptide-mediated shift in secretion profile of lymphocytes from pro-inflammatory to anti-inflammatory cytokines.
University Of Bristol
03/12/15
20150071960

Human inkt cell activation using glycolipids with altered glycosyl groups


Glycosphingolipids (gsls) bearing α-glucose (α-glc) that preferentially stimulate human invariant nkt (inkt) cells are provided. Gsls with α-glucose (α-glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with α-galactose (α-gal) are disclosed.
Academia Sinica
03/05/15
20150064787

Host cell modification with artificial endosymbionts


The present invention is directed generally to host cells with artificial endosymbionts, wherein the artificial endosymbiont and the host cell communicate with each other to alter a phenotype of the host cell. In some embodiments, the communication comprises the secretion of a polypeptide from the artificial endosymbiont into the host cell.
Bell Biosystems, Inc.
03/05/15
20150064215

Therapeutic delivery and expression system, methods and uses thereof


Therapeutic methods for cancer treatments using a combined prokaryotic-eukaryotic delivery and expression system for the delivery of multiple therapeutic factors via a modified tumor-targeted bacteria. A targeted bacteria-vector system elicits an inter-kingdom dual expression (ikde) of antitumor agents, in the nucleus or cytoplasm of eukaryotic cells, with priming and maintenance of the vector in the bacterium.
The University Of Hong Kong
03/05/15
20150064199

Cancer therapy using beta glucan and antibodies


The present invention relates to methods of using neutral soluble glucan and monoclonal antibodies for antitumor therapy. Neutral soluble beta (1,3; 1,6) glucan (nsg) enhances the tumoricidal activity of the innate immune system by binding to the c3 complement protein receptor cr3.
University Of Louisville Research Foundation, Inc.
03/05/15
20150064179

Humanized anti-il 10 antibodies for the treatment of systemic lupus erythematosus (sle)


Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (1l-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof..
Biotest Ag
02/26/15
20150057175

Method for monitoring hiv specific t cell responses


The invention relates to a method and a diagnostic kit for monitoring hiv specific t cell responses and identifying subjects capable of controlling hiv progression or preventing hiv infection altogether. The method is based on the combined use of boosted flow cytometry and toggle peptides and can cover a vastly larger set of effector functions than standard assays.
InstituciÓ Catalana De Recerca I Estudis AvanÇats


Popular terms: [SEARCH]

Cytokine topics: Antibodies, Inflammation, Specificity, Immunotherapy, Major Histocompatibility Complex, Compatibility, Combination Therapy, Histocompatibility, Immune Response, Monoclonal Antibody, Stimulator, Therapeutics, Immunostimulator, Monoclonal, Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         













0.2342

3276

2 - 1 - 74